These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). Fang L; Huber-Abel F; Teuchert M; Hendrich C; Dorst J; Schattauer D; Zettlmeissel H; Wlaschek M; Scharffetter-Kochanek K; Tumani H; Ludolph AC; Brettschneider J J Neurol Sci; 2009 Oct; 285(1-2):62-6. PubMed ID: 19523650 [TBL] [Abstract][Full Text] [Related]
45. Elevated Levels of IFN-γ in CSF and Serum of Patients with Amyotrophic Lateral Sclerosis. Liu J; Gao L; Zang D PLoS One; 2015; 10(9):e0136937. PubMed ID: 26332465 [TBL] [Abstract][Full Text] [Related]
46. Measurement of cystatin C levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Ren Y; Zhu W; Cui F; Yang F; Chen Z; Ling L; Huang X Int J Clin Exp Pathol; 2015; 8(5):5419-26. PubMed ID: 26191245 [TBL] [Abstract][Full Text] [Related]
47. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283 [TBL] [Abstract][Full Text] [Related]
48. Expression of vesicle-associated membrane-protein-associated protein B cleavage products in peripheral blood leukocytes and cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Deidda I; Galizzi G; Passantino R; Cascio C; Russo D; Colletti T; La Bella V; Guarneri P Eur J Neurol; 2014 Mar; 21(3):478-85. PubMed ID: 24372953 [TBL] [Abstract][Full Text] [Related]
50. The cerebrospinal fluid values of advanced oxidation protein products and total thiol content in patients with amyotrophic lateral sclerosis. Djordjevic G; Ljubisavljevic S; Sretenovic S; Kocic G; Stojanovic I; Stojanovic S Clin Neurol Neurosurg; 2017 Dec; 163():33-38. PubMed ID: 29055222 [TBL] [Abstract][Full Text] [Related]
51. Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis? Abdelhak A; Junker A; Brettschneider J; Kassubek J; Ludolph AC; Otto M; Tumani H Int J Mol Sci; 2015 Jul; 16(8):17565-88. PubMed ID: 26263977 [TBL] [Abstract][Full Text] [Related]
52. Decreased chloride levels of cerebrospinal fluid in patients with amyotrophic lateral sclerosis. Watanabe S; Kimura T; Suenaga K; Wada S; Tsuda K; Kasama S; Takaoka T; Kajiyama K; Takeda M; Yoshikawa H J Neurol Sci; 2009 Oct; 285(1-2):146-8. PubMed ID: 19595376 [TBL] [Abstract][Full Text] [Related]
53. Vascular endothelial growth factor attenuates neurodegenerative changes in the NSC-34 motor neuron cell line induced by cerebrospinal fluid of sporadic amyotrophic lateral sclerosis patients. Kulshreshtha D; Vijayalakshmi K; Alladi PA; Sathyaprabha TN; Nalini A; Raju TR Neurodegener Dis; 2011; 8(5):322-30. PubMed ID: 21389676 [TBL] [Abstract][Full Text] [Related]
54. Intrathecal upregulation of granulocyte colony stimulating factor and its neuroprotective actions on motor neurons in amyotrophic lateral sclerosis. Tanaka M; Kikuchi H; Ishizu T; Minohara M; Osoegawa M; Motomura K; Tateishi T; Ohyagi Y; Kira J J Neuropathol Exp Neurol; 2006 Aug; 65(8):816-25. PubMed ID: 16896315 [TBL] [Abstract][Full Text] [Related]
55. Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. Szalardy L; Zadori D; Simu M; Bencsik K; Vecsei L; Klivenyi P J Neurol Sci; 2013 Aug; 331(1-2):38-42. PubMed ID: 23706476 [TBL] [Abstract][Full Text] [Related]
56. Novel genetic variants in MAPT and alterations in tau phosphorylation in amyotrophic lateral sclerosis post-mortem motor cortex and cerebrospinal fluid. Petrozziello T; Amaral AC; Dujardin S; Farhan SMK; Chan J; Trombetta BA; Kivisäkk P; Mills AN; Bordt EA; Kim SE; Dooley PM; Commins C; Connors TR; Oakley DH; Ghosal A; Gomez-Isla T; Hyman BT; Arnold SE; Spires-Jones T; Cudkowicz ME; Berry JD; Sadri-Vakili G Brain Pathol; 2022 Mar; 32(2):e13035. PubMed ID: 34779076 [TBL] [Abstract][Full Text] [Related]
57. Tau protein as a diagnostic and prognostic biomarker in amyotrophic lateral sclerosis. Agnello L; Colletti T; Lo Sasso B; Vidali M; Spataro R; Gambino CM; Giglio RV; Piccoli T; Bivona G; La Bella V; Ciaccio M Eur J Neurol; 2021 Jun; 28(6):1868-1875. PubMed ID: 33638255 [TBL] [Abstract][Full Text] [Related]
59. Reduced levels of alpha-1-antitrypsin in cerebrospinal fluid of amyotrophic lateral sclerosis patients: a novel approach for a potential treatment. Wormser U; Mandrioli J; Vinceti M; Fini N; Sintov A; Brodsky B; Proskura E; Finkelstein Y J Neuroinflammation; 2016 Jun; 13(1):131. PubMed ID: 27245439 [TBL] [Abstract][Full Text] [Related]
60. [The measurement of phosphorylated tau in human cerebrospinal fluid as a diagnostic marker for Alzheimer's disease]. Urakami K; Ito N; Arai H; Ishiguro K; Ohno H; Nakashima K Seishin Shinkeigaku Zasshi; 2003; 105(4):393-7. PubMed ID: 12806900 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]